One of the approvals is for Ebglyss, a treatment for atopic dermatitis that could displace the current market leader, ...

Ladies and gentlemen, thank you for standing-by, and welcome to the Lilly Q3 2024 Earnings Call. [Operator Instructions] I ...

The company has two rising stars that could soon boost revenue considerably. The FDA approved Kisunla as a treatment for ...

Eli Lilly & Co. reported its results for the third quarter of 2024, with revenue up 20% y/y but failing to meet market ...

Maze has revealed positive outcome from the Phase I trial assessing oral MZE829, being developed to treat APOL1 kidney ...

Leerink Partners analyst David Risinger has maintained their bullish stance on LLY stock, giving a Buy rating today. David Risinger’s ...

The ADapt study assessed the efficacy and safety of EBGLYSS in individuals who had previously been treated with dupilumab.

Eli Lilly (NYSE:LLY) received approval from the Hong Kong government to launch its weight-loss drug—Mounjaro, with sales ...

INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY) announced that its drug EBGLYSS, an interleukin-13 (IL-13) inhibitor, has shown to improve skin condition and reduce itchiness in patients with ...

Ebglyss proves effective in relieving dermatitis symptoms, showing promise as a substitute for Dupixent in challenging cases ...

Eli Lilly's Ebglyss improves skin and itch symptoms in eczema patients, including Dupixent-treated cases, with positive Phase ...

New results show Eli Lilly Ebglyss (lebrikizumab-lbkz) improved skin (including hand and face) and itch among patients with ...